ClinicalTrials.gg
CompletedNCT04856904STARTUpdated Jun 11, 2024Results posted

Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

A Phase 4 interventional study of Trifarotene Cream and Trifarotene Vehicle Cream in Acne Vulgaris, sponsored by Galderma R&D. Completed at 18 sites in 3 countries. Open to participants aged 17 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-06-11.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
17 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.

Enrollment
11th of 12
121 · median 507
Started
2021
with 1 other
Phase 4
3 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
9 of 12
Galderma R&D

Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 11th largest by enrollment, is one of 2 that started in 2021, is one of 3 in phase 4, and was the 7th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About trifarotene

trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 17 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing trifarotene in Acne Vulgaris as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne vulgaris
  • Trifarotene
  • AKLIEF®
  • CD5789
04

Who can participate

Ages eligible
17 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant with clinical diagnosis of acne vulgaris on the face as defined by (excluding the nose and middle zone of approximately 2 centimeter [cm]):

    1. Investigator's Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe), with the same score on both sides of the face; and
    2. A minimum of 20 inflammatory lesions (papules and pustules) in total with at least 10 on each side; and
    3. No more than 2 nodules (greater than or equal to [>=] 1 cm in diameter) on the face; and
    4. A minimum of 10 atrophic acne scars in total (>2 mm)
  • Participant with a symmetrical number of the following lesions/scars on the whole face:

    1. Inflammatory and non-inflammatory lesions; and
    2. Atrophic acne scars (minimum of 4 scars per half-face)
  • The participant is a female of non-
  • If a female of childbearing, potential uses oral that are also approve for treating acne vulgaris
  • Other protocol defined inclusion criteria could apply

Key Exclusion Criteria:

  • Participant with acne conglobata, acne fulminans, secondary acne, nodulocystic acne and acne requiring systemic treatment
  • Participant with any acne cyst on the face or with more than 3 excoriated acne lesions
  • Participant with known active or chronic allergies or suspected allergy to trifarotene or of the formulation
  • Participant with facial dermal conditions (for example, tattoo, skin abrasion, eczema, sunburned skin, scars, nevi, etc.) that may interfere with study assessments in the opinion of the investigator
  • Participant with known impaired hepatic or renal functions, based on medical history
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
121 participants (actual)

Study arms

  • Placebo comparator
    Trifarotene Vehicle Cream

    Drug: Trifarotene Vehicle Cream

  • Experimental
    Trifarotene (CD5789) 50 mcg/g Cream

    Drug: Trifarotene Cream

Interventions

  • Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks

    Also known as: AKLIEF®

  • DrugTrifarotene Vehicle Cream

    Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half Face at Week 24

    The scars were counted according to their size defined in two categories using 2 millimeter (mm) and 4 mm punch biopsy tools for size classification: 1) atrophic scars 2 to 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types; 2) atrophic scars greater than (\>) 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types. Each type of atrophic acne scar was counted separately for each half-face by the evaluator for following regions: right forehead, right cheek, right side of the chin, left forehead, left cheek and left side of the chin. To obtain the total number of atrophic scars per half-face, atrophic acne scar counts for each half-face was added.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half-Face up to Week 20

    The scars were counted according to their size defined in two categories using 2 mm and 4 mm punch biopsy tools for size classification: 1) atrophic scars 2 to 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types; 2) atrophic scars \> 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types. Each type of atrophic acne scar was counted separately for each half-face by the evaluator for following regions: right forehead, right cheek, right side of the chin, left forehead, left cheek and left side of the chin. To obtain the total number of atrophic scars per half-face, atrophic acne scar counts for each half-face was added.

    Time frame: Baseline, up to Week 20

07

Results

Posted Jun 11, 2024

Participant flow

The study was conducted at 20 sites in the United States, Canada, and France.

Participant flow — Overall Study
MilestoneTrifarotene 50mcg/g CreamTrifarotene Vehicle Cream
Started121121
Completed9999
Not completed2222
Withdrew: Physician decision11
Withdrew: Withdrawal by subject1313
Withdrew: Adverse event11
Withdrew: Non-compliance with study drug11
Withdrew: Lost to follow-up44
Withdrew: Withdrawal by subject11
Withdrew: Protocol violation11

Outcome measures

PrimaryAbsolute Change From Baseline in Total Atrophic Acne Scar Count Per Half Face at Week 24

The scars were counted according to their size defined in two categories using 2 millimeter (mm) and 4 mm punch biopsy tools for size classification: 1) atrophic scars 2 to 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types; 2) atrophic scars greater than (\>) 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types. Each type of atrophic acne scar was counted separately for each half-face by the evaluator for following regions: right forehead, right cheek, right side of the chin, left forehead, left cheek and left side of the chin. To obtain the total number of atrophic scars per half-face, atrophic acne scar counts for each half-face was added.

Time frame:
Baseline, Week 24
Reported as:
Mean · atrophic acne scars
Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half Face at Week 24
atrophic acne scarsTrifarotene 50mcg/g CreamTrifarotene Vehicle Cream
Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half Face at Week 24-5.9 ± 0.51-2.7 ± 0.37
Statistical analysis
  • Trifarotene 50mcg/g Cream vs Trifarotene Vehicle Cream · Student's t-test for paired samples · p = < 0.0001 · Bilateral difference: -3.2 · 95% CI -4.4 to -2
SecondaryAbsolute Change From Baseline in Total Atrophic Acne Scar Count Per Half-Face up to Week 20

The scars were counted according to their size defined in two categories using 2 mm and 4 mm punch biopsy tools for size classification: 1) atrophic scars 2 to 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types; 2) atrophic scars \> 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types. Each type of atrophic acne scar was counted separately for each half-face by the evaluator for following regions: right forehead, right cheek, right side of the chin, left forehead, left cheek and left side of the chin. To obtain the total number of atrophic scars per half-face, atrophic acne scar counts for each half-face was added.

Time frame:
Baseline, up to Week 20
Reported as:
Mean · atrophic acne scars
Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half-Face up to Week 20
atrophic acne scarsTrifarotene 50mcg/g CreamTrifarotene Vehicle Cream
Change at Week 1-0.3 ± 0.21-0.3 ± 0.16
Change at Week 2-0.9 ± 0.26-0.4 ± 0.11
Change at Week 4-1.5 ± 0.27-0.7 ± 0.18
Change at Week 8-2.5 ± 0.30-1.1 ± 0.30
Change at Week 12-3.8 ± 0.37-1.7 ± 0.32
Change at Week 16-4.4 ± 0.40-1.7 ± 0.47
Change at Week 20-5.0 ± 0.47-2.5 ± 0.33
Statistical analysis
  • Trifarotene 50mcg/g Cream vs Trifarotene Vehicle Cream · Student's t-test for paired samples · p = = 0.9476 · Bilateral difference: 0 · 95% CI -0.3 to 0.3
  • Trifarotene 50mcg/g Cream vs Trifarotene Vehicle Cream · Student's t-test for paired samples · p = = 0.0248 · Bilateral difference: -0.6 · 95% CI -1.1 to -0.1
  • Trifarotene 50mcg/g Cream vs Trifarotene Vehicle Cream · Student's t-test for paired samples · p = = 0.0072 · Bilateral difference: -0.8 · 95% CI -1.4 to -0.2
  • Trifarotene 50mcg/g Cream vs Trifarotene Vehicle Cream · Student's t-test for paired samples · p = < 0.0001 · Bilateral difference: -1.4 · 95% CI -2.1 to -0.7
  • Trifarotene 50mcg/g Cream vs Trifarotene Vehicle Cream · Student's t-test for paired samples · p = < 0.0001 · Bilateral difference: -2.1 · 95% CI -2.9 to -1.3
  • Trifarotene 50mcg/g Cream vs Trifarotene Vehicle Cream · Student's t-test for paired samples · p = < 0.0001 · Bilateral difference: -2.7 · 95% CI -3.8 to -1.6
  • Trifarotene 50mcg/g Cream vs Trifarotene Vehicle Cream · Student's t-test for paired samples · p = < 0.0001 · Bilateral difference: -2.5 · 95% CI -3.5 to -1.5

Adverse events

Collected over From screening up to Week 28. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trifarotene 50mcg/g Cream0/121 (0%)0/121 (0%)7/121 (5.8%)
Trifarotene Vehicle Cream0/121 (0%)0/121 (0%)3/121 (2.5%)
All Acne Vulgaris Participants0/121 (0%)0/121 (0%)33/121 (27.3%)
Most frequent other events
Showing 10 of 39
Most frequent other events
EventTrifarotene 50mcg/g CreamTrifarotene Vehicle CreamAll Acne Vulgaris Participants
COVID-19Infections and infestations0/1210/12110/121
NasopharyngitisInfections and infestations0/1210/1212/121
PruritusSkin and subcutaneous tissue disorders1/1211/1212/121
RashSkin and subcutaneous tissue disorders1/1210/1212/121
Skin tightnessSkin and subcutaneous tissue disorders2/1211/1212/121
Skin lacerationInjury, poisoning and procedural complications1/1211/1212/121
SARS-CoV-2 test positiveInvestigations0/1210/1212/121
Gastroenteritis viralInfections and infestations0/1210/1211/121
Kidney infectionInfections and infestations0/1210/1211/121
Tooth abscessInfections and infestations0/1210/1211/121

Baseline characteristics

Intent to treat (ITT) population included all randomized partcipants.

Age, Continuous
Age, Continuous(years)All Acne Vulgaris Participants
Mean22.9 ± 5.12
Sex: Female, Male
Sex: Female, Male(Participants)All Acne Vulgaris Participants
Female88
Male33
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Acne Vulgaris Participants
Hispanic or Latino26
Not Hispanic or Latino95
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Acne Vulgaris Participants
American Indian or Alaska Native0
Asian12
Native Hawaiian or Other Pacific Islander0
Black or African American9
White97
More than one race0
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(count of participants)All Acne Vulgaris Participants
Canada9
United States110
France2
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)All Acne Vulgaris Participants
Type I7
Type II43
Type III31
Type IV26
Type V11
Type VI3
08

Study locations

18 sites
  • Galderma Investigational Site #8873
    Scottsdale, Arizona 85260, United States
  • Galderma Investigational Site #8447
    Fort Smith, Arkansas 72916, United States
  • Galderma Investigational Site #8608
    Santa Monica, California 90404, United States
  • Galderma Investigational Site #9928
    Boynton Beach, Florida 33437, United States
  • Galderma Investigational Site #8295
    Miami, Florida 33136, United States
  • Galderma Investigational Site #8883
    Miramar, Florida 33027, United States
  • Galderma Investigational Site #8189
    Snellville, Georgia 30078, United States
  • Galderma Investigational Site #8367
    Arlington Heights, Illinois 60005, United States
  • Galderma Investigational Site #8838
    Darien, Illinois 60561, United States
  • Galderma Investigational Site #8601
    Metairie, Louisiana 70001, United States
  • Galderma Investigational Site #9936
    New Orleans, Louisiana 70130, United States
  • Galderma Investigational Site #8108
    Las Vegas, Nevada 89148, United States
  • Galderma Investigational Site #8881
    Stony Brook, New York 11790, United States
  • Galderma Investigational Site #8886
    Sugarloaf, Pennsylvania 18249, United States
  • Galderma Investigational Site #9920
    Arlington, Texas 76011, United States
  • Galderma Investigational Site #9918
    Peterborough, Ontario, Canada
  • Galderma Investigational Site #9927
    Saint-Jérôme, Quebec, Canada
  • Galderma Investigational Site #6167
    Nantes, 44093, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Feb 2023, 20 months.

Results were first posted in Jun 2024, 1 year 4 months after primary completion.

Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 20 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2021
First posted
Apr 23, 2021
StartActual
May 28, 2021
Primary completionActual
Feb 8, 2023
CompletionActual
Jun 30, 2023
Results first posted
Jun 11, 2024
Last update
Jun 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04856904
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Apr 23, 2021
Start date
May 28, 2021
Primary completion
Feb 8, 2023
Completion
Jun 30, 2023
Results posted
Jun 11, 2024
Last update
Jun 11, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trifarotene

Start the discussion